Key result
Extended-duration postdischarge thromboprophylaxis with enoxaparin significantly reduced the incidence of DVT compared to placebo (2.8% vs 41.2%; P<0.001) in patients undergoing ACL surgery.
Why the study?
Does extended-duration postdischarge thromboprophylaxis with enoxaparin reduce the incidence of DVT and PE in patients who had undergone arthroscopic surgery of the ACL?
RCT (n=175)
Double-blind
Randomized
No
Does extended-duration postdischarge thromboprophylaxis with enoxaparin reduce the incidence of DVT and PE in patients who had undergone arthroscopic surgery of the ACL?
Absolute Event Rate: 2.8% vs 41.2%
p-value: p=<.001
Extended-duration postdischarge thromboprophylaxis with enoxaparin for 20 days significantly reduces the incidence of DVT in ACL surgery patients without increasing bleeding risk.
No takes yet. Share an insight, caveat, or question.
Supports extended postdischarge enoxaparin after ACL surgery; extends thromboprophylaxis evidence to arthroscopic reconstruction.
Marlovits et al. (2007) conducted an RCT in Arthroscopic surgery of the anterior cruciate ligament (ACL) (n=175). Enoxaparin vs. Placebo was evaluated on Incidences of symptomatic and asymptomatic deep vein thrombosis (DVT) and pulmonary embolism (PE) (p=<.001). Extended-duration postdischarge thromboprophylaxis with enoxaparin significantly reduced the incidence of DVT compared to placebo (2.8% vs 41.2%; P<0.001) in patients undergoing ACL surgery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: